First Popliteal Aneurysm Patient Successfully Treated With Cardiatis FluidSmart 3D Multilayer Stent System

Share Article

Cardiatis, SA announces successful treatment of the first popliteal aneurysm patient with the Cardiatis FluidSmart 3D Multilayer Braided Stent. FluidSmart, an investigational device in the European Union, is a next generation technology for endovascular aneurysm repair.

Cardiatis, SA announced today the successful treatment of the first popliteal aneurysm patient with the Cardiatis FluidSmart 3D Multilayer Braided Stent. FluidSmart, an investigational device in the European Union, is a next generation technology for endovascular aneurysm repair.

The procedure was performed by Professor Antonios Polydorou at Agios Panteleimon General Hospital of Nikaia in Athens, Greece. The first treated patient, a 75-year old male, on December 14th 2006 underwent a minimally invasive endovascular procedure that placed a Cardiatis FluidSmart hemodynamic modulating stent to treat a 5 cm popliteal aneurysm. Post procedural angiogram showed successful deployment and reduction in flow within aneurysm.

On February 20th 2007, two months following stent implantation, angiography revealed the formation of an organized thrombus within the aneurysm with reduction in aneurysm size.

On July 10th, 2007 the seven-month follow up angiogram revealed complete exclusion of aneurysm from circulation. As of the time of writing, the aneurysm remains excluded from circulation with no recanalization and the patient has resumed full functionality.

"Though rare, popliteal aneurysms can result in severe morbidity. Open surgical repair remains the main method for managing them, however Cardiatis FluidSmart technology offers a novel endovascular approach for difficult to operate cases" stated Professor Polydorou

Popliteal artery aneurysms are the most common peripheral artery aneurysms accounting for up to 85% of the total aneurysms in the periphery. More than 95% of peripheral artery aneurysms occur in males, and the average age of patients at presentation is 65 years. Atherosclerosis appears to be the etiology in more than 90% of cases.

"We are glad that our technology proved to be of help in this humanitarian case" said Noureddine Frid, Cardiatis president and chief executive officer. "We will continue to develop our technology for the endovascular repair of aneurysm in main locations like the aorta and the brain."

About Cardiatis
Cardiatis, an innovative medical technology company located in Belgium, is focused on developing its patented FluidSmart 3D multilayer stent technology platform, a next generation technology for endovascular aneurysm repair. Additional information can be found on Cardiatis web site at http://www.cardiatis.com.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Margy Waugh
Visit website